Marie Csete, MD, PhD, ConeSight Therapeutics, Pasadena, CA, talks on advancements in advanced therapies that are impacting the ophthalmological space. Induced pluripotent stem cell (iPSC)-based retinal pigment epithelium (RPE) cell products have made large strides within the field, and genetic engineering has enabled allogeneic therapies to be successfully delivered in patients. Treatment of glaucoma is also on the horizon with the development of cell therapies based on retinal ganglion cells. This interview took place at Meeting on the Mesa 2021.